Arbidol Attenuates Liver Fibrosis and Activation of Hepatic Stellate Cells by Blocking TGF-β1 Signaling

Oral administration of Arbidol significantly ameliorated bile duct ligated-induced liver injury/fibrosis as reflected by decreased serum levels of alanine aminotransferase, aspartate aminotransferase, reduced collagen deposition, and diminished mRNA expression of fibrosis markers.